Literature DB >> 12667209

Identification of a novel human leucocyte antigen-A*01-restricted cytotoxic T-lymphocyte epitope in the respiratory syncytial virus fusion protein.

Michael T Rock1, James E Crowe.   

Abstract

Virus-specific cytotoxic T lymphocytes (CTL) play a major role in the clearance of respiratory syncytial virus (RSV) infection. To begin monitoring the immunological response to infection, especially in infants, it is important to identify human leucocyte antigen (HLA)-restricted CTL epitopes. Herein, we used a novel, comprehensive peptide panel containing all possible 8-, 9- and 10-mer peptides spanning the RSV fusion protein to screen for novel HLA-restricted T-cell epitopes. These peptide sets were synthesized as 10-mer peptides overlapping by nine amino acids and contained corresponding 8- and 9-mer peptides generated by C-terminal truncation. Unselected and uncultured peripheral blood mononuclear cells from healthy adult subjects were screened by interferon-gamma (IFN-gamma) Elispot assays against the peptide panel. Seven of 19 subjects displayed positive responses against 10 of the 565 peptides analysed. An HLA-A*01-restricted CTL epitope detected in three healthy adult subjects is characterized. This is the first RSV-specific memory CTL response identified in the fusion protein of RSV.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12667209      PMCID: PMC1782928          DOI: 10.1046/j.1365-2567.2003.01619.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  34 in total

Review 1.  SYFPEITHI: database for MHC ligands and peptide motifs.

Authors:  H Rammensee; J Bachmann; N P Emmerich; O A Bachor; S Stevanović
Journal:  Immunogenetics       Date:  1999-11       Impact factor: 2.846

2.  Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion.

Authors:  L González-Reyes; M B Ruiz-Argüello; B García-Barreno; L Calder; J A López; J P Albar; J J Skehel; D C Wiley; J A Melero
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-07       Impact factor: 11.205

3.  HLA class I-restricted cytotoxic T-cell epitopes of the respiratory syncytial virus fusion protein.

Authors:  A H Brandenburg; L de Waal; H H Timmerman; P Hoogerhout; R L de Swart; A D Osterhaus
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  Specific human cytotoxic T cells recognize B-cell lines persistently infected with respiratory syncytial virus.

Authors:  C R Bangham; A J McMichael
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

5.  Characterization of a novel respiratory syncytial virus-specific human cytotoxic T-lymphocyte epitope.

Authors:  P J Goulder; F Lechner; P Klenerman; K McIntosh; B D Walker
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

6.  Visualization and characterization of respiratory syncytial virus F-specific CD8(+) T cells during experimental virus infection.

Authors:  J Chang; A Srikiatkhachorn; T J Braciale
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

7.  Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity.

Authors:  R A Olmsted; N Elango; G A Prince; B R Murphy; P R Johnson; B Moss; R M Chanock; P L Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

8.  Clearance of persistent respiratory syncytial virus infections in immunodeficient mice following transfer of primed T cells.

Authors:  M J Cannon; E J Stott; G Taylor; B A Askonas
Journal:  Immunology       Date:  1987-09       Impact factor: 7.397

9.  Cytotoxic T cell specificity for respiratory syncytial virus proteins: fusion protein is an important target antigen.

Authors:  R M Pemberton; M J Cannon; P J Openshaw; L A Ball; G W Wertz; B A Askonas
Journal:  J Gen Virol       Date:  1987-08       Impact factor: 3.891

10.  Respiratory syncytial viral infection in children with compromised immune function.

Authors:  C B Hall; K R Powell; N E MacDonald; C L Gala; M E Menegus; S C Suffin; H J Cohen
Journal:  N Engl J Med       Date:  1986-07-10       Impact factor: 91.245

View more
  24 in total

1.  Conserved cysteine residues within the attachment G glycoprotein of respiratory syncytial virus play a critical role in the enhancement of cytotoxic T-lymphocyte responses.

Authors:  Guillermina A Melendi; Dowd Bridget; Ana C Monsalvo; Federico F Laham; Patricio Acosta; Maria Florencia Delgado; Fernando P Polack; Pablo M Irusta
Journal:  Virus Genes       Date:  2010-11-04       Impact factor: 2.332

2.  Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein.

Authors:  Anu Cherukuri; Kathryn Patton; Robert A Gasser; Fengrong Zuo; Jennifer Woo; Mark T Esser; Roderick S Tang
Journal:  Clin Vaccine Immunol       Date:  2012-12-12

3.  Programmed death-1 impairs secondary effector lung CD8⁺ T cells during respiratory virus reinfection.

Authors:  John J Erickson; Meredith C Rogers; Andrew K Hastings; Sharon J Tollefson; John V Williams
Journal:  J Immunol       Date:  2014-10-22       Impact factor: 5.422

4.  Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults.

Authors:  C Buddy Creech; Cornelia L Dekker; Dora Ho; Shanda Phillips; Sally Mackey; Cristina Murray-Krezan; Maria Grazia Pau; Jenny Hendriks; Valerie Brown; Leonard G Dally; Isabella Versteege; Kathryn M Edwards
Journal:  Hum Vaccin Immunother       Date:  2013-08-17       Impact factor: 3.452

5.  Tissue-specific regulation of CD8+ T-lymphocyte immunodominance in respiratory syncytial virus infection.

Authors:  Sujin Lee; Scott A Miller; David W Wright; Michael T Rock; James E Crowe
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

6.  Gold nanorod vaccine for respiratory syncytial virus.

Authors:  John W Stone; Natalie J Thornburg; David L Blum; Sam J Kuhn; David W Wright; James E Crowe
Journal:  Nanotechnology       Date:  2013-06-25       Impact factor: 3.874

7.  Identification of potential human respiratory syncytial virus and metapneumovirus T cell epitopes using computational prediction and MHC binding assays.

Authors:  Michael T Rock; Brett A McKinney; Sandra M Yoder; Catherine E Prudom; David W Wright; James E Crowe
Journal:  J Immunol Methods       Date:  2011-08-11       Impact factor: 2.303

8.  Amino acid variation within the fusion protein of respiratory syncytial virus subtype A and B strains during annual epidemics in South Africa.

Authors:  Elizabeth Agenbach; Caroline T Tiemessen; Marietjie Venter
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.332

9.  Enhancement of the CD8+ T cell response to a subdominant epitope of respiratory syncytial virus by deletion of an immunodominant epitope.

Authors:  Hoyin Mok; Sujin Lee; David W Wright; James E Crowe
Journal:  Vaccine       Date:  2008-07-26       Impact factor: 3.641

10.  Multiple, non-conserved, internal viral ligands naturally presented by HLA-B27 in human respiratory syncytial virus-infected cells.

Authors:  Susana Infantes; Elena Lorente; Eilon Barnea; Ilan Beer; Juan José Cragnolini; Ruth García; Fátima Lasala; Mercedes Jiménez; Arie Admon; Daniel López
Journal:  Mol Cell Proteomics       Date:  2010-01-15       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.